Sundrug Co (9989) AI Stock Analysis

• Market Cap: $562.64B
• Dividend Yield: 2.69%
• Average Volume (3M): 313.74K
• Price to Earnings (P/E): 17.9
• Beta (1Y): 0.35
• Revenue Growth: 6.64%
• EPS Growth: 6.38%
• Country: JP
• Employees: 6,662
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 67.92
• Shares Outstanding: 119,331,184
• 10 Day Avg. Volume: 470,460
• 30 Day Avg. Volume: 313,740
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 2.54
• Enterprise Value/Ebitda: 9.35
• 1Y Price Target: $5,501.47
• Price Target Upside: 13.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 73 Outperform
• Price Target: ¥4,997.00 ▲(3.27% Upside)

Sundrug Co's strong financial performance is the most significant factor contributing to the overall score, supported by solid revenue growth and efficient cash generation. The technical analysis indicates a neutral market position, with some potential for upward movement due to oversold conditions. Valuation metrics suggest the stock is fairly priced with a decent dividend yield. The absence of earnings call data and notable corporate events limits additional insights.

Sundrug Co Business Overview & Revenue Model

Company Description

Sundrug Co., Ltd. is a prominent Japanese company operating in the retail sector, primarily focusing on the health and beauty industry. The company runs a chain of drugstores offering a wide range of products including pharmaceuticals, cosmetics, health foods, and daily necessities. Sundrug is recognized for its extensive network of stores across Japan, providing customers with convenient access to health and wellness products.

How the Company Makes Money

Sundrug Co. generates revenue primarily through the sale of pharmaceuticals, over-the-counter medicines, cosmetics, and health-related goods in its retail stores. The company capitalizes on its widespread retail presence and brand reputation to attract a large customer base. Additionally, Sundrug may engage in strategic partnerships with health and beauty product manufacturers to offer exclusive or premium products, thereby enhancing its product offerings and profit margins. Other revenue streams could include loyalty programs and online sales, although the core business remains its physical retail operations.

Sundrug Co Financial Statement Overview

Summary

Sundrug Co demonstrates robust financial health with consistent revenue and profit growth. It maintains strong profit margins and a solid balance sheet with low leverage and high equity. Cash flow generation is excellent, although there is room for improvement in converting profits into free cash flow.

Income Statement

Sundrug Co has demonstrated consistent revenue growth, with a 6.66% increase in the most recent year. The company maintains healthy profit margins with a gross profit margin of 25.45% and a net profit margin of 3.84% for the latest period. EBIT and EBITDA margins are strong at 5.55% and 7.61% respectively, indicating efficient operational performance. Overall, the income statement reflects a robust financial health with a positive growth trajectory.

Balance Sheet

The balance sheet of Sundrug Co is solid, characterized by a low debt-to-equity ratio of 0.14, suggesting minimal leverage risk. The company has a strong equity ratio of 60.73%, indicating a healthy reliance on equity financing. Return on equity stands at 11.40%, highlighting efficient use of equity to generate profits. The company exhibits financial stability with a strong equity base and manageable debt levels.

Cash Flow

Sundrug Co's cash flow statement shows a positive free cash flow growth rate of 160.31% recently, demonstrating effective cash generation capabilities. The operating cash flow to net income ratio stands at 1.34, indicating strong cash generation relative to reported profits. The free cash flow to net income ratio of 0.25 suggests room for improvement in converting profits into free cash flow. Overall, the cash flow position is strong, with excellent cash generation and growth.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	801.81B	751.78B	690.46B	648.73B	634.31B
Gross Profit	204.09B	189.32B	171.95B	156.51B	158.55B
EBITDA	61.02B	56.53B	49.52B	44.26B	46.01B
Net Income	30.75B	29.13B	25.70B	23.85B	25.33B
Balance Sheet
Total Assets	444.01B	420.21B	360.67B	325.77B	308.53B
Cash, Cash Equivalents and Short-Term Investments	64.96B	69.70B	80.87B	89.33B	86.50B
Total Debt	38.67B	35.00B	939.00M	529.00M	114.00M
Total Liabilities	174.29B	167.12B	124.34B	105.18B	103.37B
Stockholders Equity	269.71B	253.09B	236.33B	220.59B	205.16B
Cash Flow
Free Cash Flow	7.71B	2.96B	11.27B	11.89B	15.29B
Operating Cash Flow	41.16B	41.19B	37.38B	31.68B	31.76B
Investing Cash Flow	-35.37B	-74.85B	-28.51B	-20.66B	-17.90B
Financing Cash Flow	-10.60B	22.49B	-17.33B	-8.19B	-8.06B

Sundrug Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4839.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9989, the sentiment is Positive. The current price of 4839 is above the 20-day moving average (MA) of 4631.80, above the 50-day MA of 4538.16, and above the 200-day MA of 4228.71, indicating a bullish trend. The MACD of 72.17 indicates Negative momentum. The RSI at 62.29 is Neutral, neither overbought nor oversold. The STOCH value of 77.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9989.

Sundrug Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3549	76 Outperform	¥427.63B	23.20		0.34%	14.79%	35.84%
3141	75 Outperform	¥544.22B	29.65		1.37%	7.43%	-24.81%
7649	75 Outperform	$717.53B	16.76	16.26%	0.89%	20.18%	82.36%
9989	73 Outperform	$562.64B	17.92	12.18%	2.69%	6.64%	6.38%
3391	71 Outperform	$558.00B	25.56	4.93%	2.34%	4.63%	-47.30%
3349	70 Neutral	¥769.89B	24.75		0.73%	4.81%	26.65%
Sector *	65 Neutral	¥352.94B	11.56	-1.45%	2.37%	9.60%	-12.34%

Sundrug Co Corporate Events

Sundrug Co. Completes Treasury Share Disposal for Stock Compensation

Sundrug Co., Ltd. has completed the payment for the disposal of 15,600 treasury shares as restricted stock compensation, a decision made during the Board of Directors’ meeting on June 20, 2025. This move is aimed at aligning the interests of its directors and executive officers with the company’s performance, potentially impacting its corporate governance and stakeholder relations.

The most recent analyst rating on (JP:9989) stock is a Buy with a Yen5400.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.

Sundrug Co. Announces Treasury Shares Disposal for Executive Incentives

Sundrug Co., Ltd. announced the disposal of 15,600 treasury shares as part of a restricted stock compensation plan aimed at incentivizing directors and executive officers to align with shareholder interests and sustainably increase corporate value. This initiative reflects the company’s commitment to fostering shared value with stakeholders and enhancing its market position.

The most recent analyst rating on (JP:9989) stock is a Buy with a Yen4700.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.

Sundrug Co. Reports Strong Financial Performance for FY 2025

Sundrug Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a notable increase in net sales and profits compared to the previous year. The company experienced a 6.7% rise in net sales, reaching 801,811 million yen, and a 5.6% increase in profit attributable to owners of the parent, totaling 30,750 million yen. The financial results indicate a strong performance, with improvements in operating and ordinary profits, reflecting the company’s robust market positioning and operational efficiency. The company also announced an increase in annual dividends, demonstrating its commitment to returning value to shareholders.

The most recent analyst rating on (JP:9989) stock is a Buy with a Yen4100.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.